Protein S Deficiency

Protein S deficiency is a hereditary or acquired deficiency of protein S, a vitamin K–dependent cofactor for activated protein C, resulting in impaired anticoagulation and an increased risk of venous thromboembolism.

Epidemiology

Protein S deficiency alone confers a moderate thrombotic risk (OR ~5.4 for VTE) ^[1]. However, clinically significant thrombosis usually requires an additional "hit" — a provocation. Think of it as a two-hit model: the genetic deficiency is the first hit, and a provoking factor is the second.

Risk factors that "unmask" thrombosis in Protein S-deficient individuals:

Category	Examples	Mechanism
Immobilisation	Prolonged bed rest, long-haul flights ( > 6 h), post-operative	Venous stasis (Virchow's triad)
Surgery/Trauma	Orthopaedic surgery, pelvic surgery	Endothelial injury + stasis
Pregnancy/Puerperium	Especially 3rd trimester and 6 weeks postpartum	Physiological ↑ coagulation factors; Protein S levels fall in pregnancy ^[1]
OC pills / HRT	Combined oral contraceptive pills (2–4× baseline risk)	High-dose oestrogen → ↑ coagulation factor production ^[4]
Malignancy	Adenocarcinoma (mucin-secreting), MPN	Hypercoagulability via tissue factor release
Obesity	BMI > 30	Chronic low-grade inflammation, venous stasis
Smoking		Endothelial dysfunction
Co-existing thrombophilia	Combined Protein S deficiency + Factor V Leiden (in non-Chinese), or APLS	Multiplicative thrombotic risk

Exam Pearl

Under normal circumstances, levels of natural anticoagulants in our body do NOT stay constant — they change throughout life. In pregnancy, levels change in different trimesters. Childhood has different reference ranges. ^[1] This is critical because it means you cannot diagnose Protein S deficiency during pregnancy — levels are physiologically low!

Anatomy and Functional Basis

Aetiology

Mode of inheritance: Autosomal dominant ^[1]

The gene involved is PROS1 (also written as PROS), located on chromosome 3q11.1 ^[4]. There is a pseudogene (PROSP) nearby, which can complicate molecular diagnosis.

Classification into Three Types

Three types of Protein S deficiency exist: ^[1]

Type	Total Protein S (Ag)	Free Protein S (Ag)	Protein S Activity	Mechanism
Type I (Quantitative)	↓	↓	↓	Reduced synthesis of Protein S (classic quantitative deficiency)
Type II (Qualitative)	Normal	Normal	↓	Dysfunctional Protein S molecule (normal amount but doesn't work properly)
Type III (Quantitative, free)	Normal	↓	↓	Normal total Protein S but increased binding to C4BP → reduced free (active) Protein S

Clinical pearl: Types I and III are now thought to be allelic variants of the same genetic defect (the same PROS1 mutation can manifest as Type I in youth and Type III in older age as total Protein S normalises but free Protein S remains low). Type II is the rarest.

Heterozygous deficiency: moderate thrombotic risk (OR ~5.4), first VTE typically in young adulthood.
Homozygous deficiency: extremely rare, presents with neonatal purpura fulminans — widespread DIC and skin necrosis within hours to days of birth, often fatal without treatment.

Acquired causes are far more common than inherited deficiency and must always be excluded before diagnosing inherited Protein S deficiency.

Cause	Mechanism
Pregnancy	↑ C4BP (acute-phase reactant) → more binding → ↓ free Protein S; also ↑ overall procoagulant state
OC pills / HRT (oestrogen-containing)	Oestrogen ↑ C4BP production → ↓ free Protein S
Liver disease	↓ hepatic synthesis of Protein S (liver makes most clotting factors AND natural anticoagulants)
Vitamin K deficiency / Warfarin therapy	Protein S is vitamin K-dependent → ↓ synthesis
Acute thrombosis	All three natural anticoagulants are getting consumed in the clot ^[1] → transient ↓
DIC	Consumption of anticoagulants in widespread clotting
Nephrotic syndrome	Urinary loss of Protein S (and Antithrombin III)
Inflammatory states / Infection / Autoimmune disease (e.g. SLE, IBD)	↑ C4BP (acute-phase reactant) → ↓ free Protein S; also direct autoimmune destruction (anti-Protein S antibodies in SLE)
HIV infection	Mechanism unclear; possibly autoantibodies or ↓ synthesis
L-asparaginase therapy	Inhibits hepatic protein synthesis
Sickle cell disease	Chronic haemolysis and endothelial dysfunction

Critical Testing Pitfall

Acute thrombosis itself lowers all three natural anticoagulants because they are consumed in the clot. ^[1] This means you cannot reliably diagnose inherited Protein S deficiency during an acute VTE event — the levels will be falsely low. Similarly, do not test while patients are receiving anticoagulants (withhold warfarin × 2 weeks, DOAC × at least 2 days) ^[6]. Test at least 2–4 weeks after the acute event and off anticoagulation.

Pathophysiology

The pathophysiology connects directly to the functional anatomy described above:

Classification

	Inherited	Acquired
Frequency	Rare (~0.9% of general population)	Common
Inheritance	Autosomal dominant	N/A
Gene	PROS1 on 3q11.1	N/A
Subtypes	Type I, II, III	By underlying cause
Onset	Young adult (typically < 40 y)	Any age

Zygosity	Free Protein S Level	Clinical Severity
Heterozygous	~30–60% of normal	Moderate risk (OR ~5.4 for VTE); may be asymptomatic lifelong or have VTE with provocation
Homozygous	Near 0%	Neonatal purpura fulminans; DIC; life-threatening without immediate treatment

Antithrombin deficiency is the most clinically severe: ^[1]

Condition	OR for VTE	Key Feature
Antithrombin deficiency	~16.3	Most severe; ~70% have VTE before age 60; VTE often resistant to normal doses of heparin
Protein C deficiency	~7.5	A/w warfarin-induced skin necrosis
Protein S deficiency	~5.4	Most common of the three; cofactor for Protein C

Clinical Features

Symptoms

Most patients with heterozygous Protein S deficiency are asymptomatic until a provoking event triggers their first thrombotic episode. The clinical features are those of VTE — DVT and/or PE.

Symptom	Pathophysiological Basis
Unilateral leg pain (calf or thigh)	Thrombus within the deep venous system causes local inflammation and distension of the vein wall → nociceptor stimulation
Unilateral leg swelling	Thrombus obstructs venous return → hydrostatic pressure rises distal to the obstruction → transudation of fluid into interstitial space → pitting oedema
Feeling of heaviness in the affected limb	Increased interstitial fluid and venous congestion

Symptom	Pathophysiological Basis
Acute dyspnoea	Embolus lodges in pulmonary artery → V/Q mismatch (perfusion defect with maintained ventilation) → hypoxaemia; also reflexive bronchoconstriction in affected segments
Pleuritic chest pain	Peripheral emboli cause pulmonary infarction → inflammation of visceral pleura → sharp pain worse on inspiration
Cough	Irritation of airways from pulmonary infarction and local inflammation
Haemoptysis	Pulmonary infarction → ischaemic necrosis of lung parenchyma → blood leaks into alveoli
Syncope / Presyncope	Massive PE → acute right heart failure → ↓ cardiac output → cerebral hypoperfusion
Sudden death	Massive saddle embolus → complete obstruction of pulmonary outflow → obstructive shock

Site	Symptoms
Cerebral venous sinus	Headache (worst headache of life), seizures, focal neurological deficits, altered consciousness
Mesenteric veins	Abdominal pain (often out of proportion to examination findings), nausea, bloody diarrhoea
Portal vein	Right upper quadrant pain, ascites, splenomegaly
Renal vein	Flank pain, haematuria, acute kidney injury

Symptom	Context
Recurrent miscarriages (particularly 2nd/3rd trimester)	Placental microvascular thrombosis → placental insufficiency → foetal loss
Skin necrosis (with warfarin)	Warfarin-induced skin necrosis — sudden painful purpuric patches, typically on fatty areas (breasts, buttocks, thighs), progressing to black eschar within first few days of warfarin initiation

Signs

Sign	Pathophysiological Basis
Unilateral pitting oedema	↑ Hydrostatic pressure distal to thrombus → fluid transudation
Increased calf circumference (measure at 10 cm below tibial tuberosity; > 3 cm difference is significant)	Oedema + venous engorgement
Erythema and warmth	Local inflammatory response to thrombus → vasodilation and ↑ blood flow to skin
Tenderness along deep vein distribution	Inflammation of vein wall (phlebitis)
Distended superficial veins	Collateral venous drainage around the obstructed deep vein
Homan's sign (calf pain on dorsiflexion — insensitive and non-specific, not recommended)	Stretching of inflamed posterior tibial veins
Low-grade fever	Systemic inflammatory response to thrombosis

Sign	Pathophysiological Basis
Tachypnoea	Hypoxaemia → ↑ respiratory drive; also dead-space ventilation increases minute ventilation demand
Tachycardia	Compensatory sympathetic response to ↓ cardiac output and hypoxaemia
Hypotension (in massive PE)	Acute RV failure → ↓ LV preload → ↓ cardiac output → obstructive shock
Elevated JVP	RV outflow obstruction → ↑ RA pressure → transmitted back to jugular veins
Loud P2 (loud pulmonary component of S2)	Acute pulmonary hypertension → forceful closure of pulmonary valve
Right parasternal heave	Acute RV dilation/strain
Pleural rub	Pulmonary infarction → pleuritis → friction between inflamed visceral and parietal pleura
Cyanosis (central)	Severe V/Q mismatch → refractory hypoxaemia
Signs of RV failure — hepatomegaly, peripheral oedema	Acute RV failure → ↑ systemic venous pressure

Sign	Basis
Widespread purpuric skin lesions progressing to necrosis	Microvascular thrombosis in dermal vessels → ischaemic necrosis of skin and subcutaneous tissue
DIC features — oozing from puncture sites, petechiae	Massive consumption of coagulation factors and platelets

Sign	Basis
Erythematous, painful patches → haemorrhagic bullae → black necrotic eschar	Microvascular thrombosis in subcutaneous fat-rich areas (breasts, buttocks, thighs) due to precipitous drop in Protein C/S before procoagulant factor levels fall
Typically occurs days 3–5 of warfarin initiation

Sign	Basis
Chronic leg swelling	Venous valve damage from prior DVT → chronic venous insufficiency → persistent oedema
Skin changes — hyperpigmentation, lipodermatosclerosis, varicose eczema	Chronic venous hypertension → haemosiderin deposition (from extravasated RBCs), fibrosis, inflammation
Venous ulcers (medial malleolus)	End-stage chronic venous insufficiency

Relevant Physiological Concepts

Feature	Antithrombin Deficiency	Protein C Deficiency	Protein S Deficiency
Gene	SERPINC1 (1q25.1)	PROC (2q13-14)	PROS1 (3q11.1)
Inheritance	AD	AD	AD
Prevalence	0.02–0.2%	0.14–0.18%	~0.9% (most common)
OR for VTE	~16.3 (most severe)	~7.5	~5.4
Mechanism	AT-III inactivates thrombin + Xa (potentiated by heparin)	APC inactivates Va + VIIIa	Cofactor for APC
Vitamin K-dependent?	No	Yes	Yes
Warfarin-induced skin necrosis	No	Yes (classically)	Yes (less commonly)
Heparin resistance	Yes (AT-III is required for heparin's mechanism)	No	No
VTE by age 60	~70%	Variable	Variable
Treatment of VTE	Higher dose LMWH; AT concentrate	Anticoagulation (indefinite)	Anticoagulation; individualise decision for indefinite anticoagulation
Special note	Loss in nephrotic syndrome (urinary)		Free vs bound (C4BP) distinction

High Yield Summary

Key Points for Protein S Deficiency:

Protein S is a vitamin K-dependent natural anticoagulant synthesised in the liver, endothelial cells, megakaryocytes, and brain cells ^[1]
It acts as a cofactor for Activated Protein C (APC), which inactivates Factor Va and Factor VIIIa ^[1]
Inherited form is autosomal dominant (PROS1, 3q11.1) with three types (I, II, III) ^[1]
Prevalence ~0.9% — the most common inherited natural anticoagulant deficiency ^[1]
OR for VTE ~5.4 (less severe than AT deficiency at 16.3 and Protein C deficiency at 7.5) ^[1]
Free Protein S is the functionally active form — ~60% is bound to C4BP and inactive ^[1]
Acquired causes are far more common — pregnancy, OC pills, liver disease, acute thrombosis, DIC, nephrotic syndrome
PT and APTT are normal — need specific thrombophilia screening
Do not test during acute VTE or on anticoagulants — falsely low results ^[6]
Factor V Leiden is NOT found in Chinese — making Protein C/S and AT deficiency relatively more important in Hong Kong ^[4]
Warfarin-induced skin necrosis can occur — always bridge with heparin
Presentations: DVT, PE, unusual-site thrombosis, recurrent miscarriage, neonatal purpura fulminans (homozygous)

Active Recall - Protein S Deficiency

Differential Diagnosis of Protein S Deficiency

When you encounter a clinical scenario that raises suspicion for Protein S deficiency — typically a young patient with unprovoked VTE, recurrent VTE, VTE at an unusual site, warfarin-induced skin necrosis, or recurrent pregnancy loss — the core task is to differentiate Protein S deficiency from other causes of the hypercoagulable/thrombophilic state. You are not really differentiating "Protein S deficiency" in isolation; you are differentiating the cause of the thrombotic tendency or the cause of a low Protein S level.

There are therefore two distinct DDx frameworks to master:

DDx of a thrombophilic state (the patient presents with VTE → what is the underlying cause?)
DDx of a low Protein S level (the lab returns a low Protein S → is it truly inherited deficiency, or is it acquired/artefactual?)

Framework 1: DDx of a Thrombophilic State (Why Did This Patient Clot?)

This is the more common clinical scenario. A patient presents with DVT, PE, or unusual-site thrombosis, and you need to work through the differential for the underlying hypercoagulable cause.

These are all autosomal dominant conditions ^[1]^[4]. They form the core DDx against which Protein S deficiency must be distinguished.

Condition	Mechanism	Distinguishing Features from Protein S Deficiency
Protein C deficiency	APC directly inactivates Factor Va and VIIIa; Protein C is the enzyme, Protein S is its cofactor	More strongly associated with warfarin-induced skin necrosis ^[4]^[9] than Protein S deficiency; lower Protein C level on specific assay; OR ~7.5
Antithrombin III deficiency	AT-III inactivates thrombin and Factor Xa (potentiated by heparin) ^[4]	Most clinically severe (OR ~16.3); ~70% have VTE before 60y; VTE often resistant to normal doses of heparin ^[4] — this heparin resistance is a key distinguishing clue
Factor V Leiden	Point mutation in Factor V gene → Arg506Gln → Factor Va becomes resistant to APC cleavage	NOT found in Chinese populations ^[4]^[9] — irrelevant in Hong Kong; tested via Activated Protein C Resistance (APCR) assay and Factor V Leiden PCR
Prothrombin G20210A mutation	Gain-of-function mutation → ↑ prothrombin levels → ↑ thrombin generation	NOT found in Chinese ^[4]; detected by specific PCR

Hong Kong DDx Priority

In ethnic Chinese patients, the relevant inherited thrombophilia DDx is essentially three conditions: Protein S deficiency, Protein C deficiency, and Antithrombin III deficiency. Factor V Leiden is NOT found in Chinese ^[4]^[9] and Prothrombin G20210A is absent/extremely rare. This is a key exam point for HKUMed — don't waste time discussing Factor V Leiden in a Chinese patient vignette.

Why is the distinction clinically important? Because management differs:

Antithrombin deficiency → may need higher dose LMWH and AT concentrate for refractory VTE ^[4]

Protein C deficiency → warfarin needs mandatory heparin bridging (higher risk of skin necrosis) ^[4]

Protein S deficiency → individualise decision for indefinite anticoagulation ^[4] (less aggressive than Protein C deficiency, where indefinite anticoagulation is generally recommended)

These are far more common than inherited causes in clinical practice.

Condition	Key Distinguishing Features
Antiphospholipid syndrome (APLS)	Recurrent DVT and miscarriages (especially 2nd/3rd trimester) ^[10]; presence of lupus anticoagulant, anti-cardiolipin Ab, anti-β2-glycoprotein I Ab on ≥2 occasions ≥12 weeks apart ^[10]; may cause prolonged APTT (paradoxically — APTT prolonged in vitro but patient is prothrombotic in vivo); can be primary or secondary to SLE
Malignancy	Most important cause of unprovoked VTE ^[4]^[9] — must always be considered; especially adenocarcinoma (mucin-secreting) ^[2]^[3], pancreatic, ovarian, lung; Trousseau syndrome (migratory superficial thrombophlebitis); may present as chronic compensated DIC
Pregnancy / Puerperium	↑ Coagulation factor production; Protein S physiologically drops ^[1]; highest risk in 3rd trimester and 6 weeks postpartum
OC pills / HRT	High-dose oestrogen → ↑ coagulation factor production ^[4]^[11]; also ↑ C4BP → ↓ free Protein S (acquired Protein S deficiency)
Nephrotic syndrome	Urinary loss of Antithrombin III (and Protein S) ^[4]^[12]; also ↑ hepatic synthesis of procoagulant factors; classically associated with renal vein thrombosis
Myeloproliferative neoplasms (MPN)	Polycythaemia vera, essential thrombocythaemia → thrombosis arterial > venous; JAK2/CALR/MPL mutations; ET with very high platelets ( > 1000) can cause acquired von Willebrand disease (paradoxical bleeding) ^[13]
PNH (Paroxysmal Nocturnal Haemoglobinuria)	Very rare in Chinese ^[4]^[9]; suspect with unexplained haemolysis + cytopenias + thrombosis (especially unusual sites like hepatic/Budd-Chiari, cerebral); diagnosed by flow cytometry for GPI-anchored proteins (CD55/CD59)
Heparin-Induced Thrombocytopenia (HIT)	Paradoxical thrombosis + thrombocytopenia 5–10 days after heparin exposure; anti-PF4/heparin antibodies
DIC	Tends to bleed (acute/decompensated) or clot (chronic/compensated) ^[6]; ↑ PT, ↑ APTT, ↓ fibrinogen, ↑ D-dimer, ↓ platelets, schistocytes on PBS ^[6]

GC Lecture Slide – Predisposing Causes of DVT and PE

Protein S & C deficiency, Antithrombin III deficiency — acquired or genetic predisposition; Immobility – leg fracture, post-operative state, heart failure, long haul flights, muscle paralysis in ICU; Oestrogens; Hypercoagulable states from systemic disease e.g. Malignancy; Antiphospholipid syndrome / SLE; Nephrotic syndrome; Instrumentation to leg veins e.g. femoral catheterisation ^[11]

Condition	Key Points
Hyperhomocysteinaemia	No data in the Chinese ^[4]; elevated homocysteine → endothelial toxicity + ↑ thrombotic risk; associated with MTHFR mutations; can be arterial or venous
Obesity	Chronic low-grade inflammation + venous stasis
Smoking	Endothelial dysfunction
Immobilisation	Pure stasis — no blood test abnormality; diagnosis of exclusion in terms of thrombophilia workup

This is the second clinical scenario: the thrombophilia screen returns a low Protein S level. Before diagnosing inherited Protein S deficiency, you must exclude acquired causes of low Protein S — which are far more common.

Acquired Cause of Low Protein S	Mechanism	How to Distinguish from Inherited
Acute thrombosis	All three natural anticoagulants are consumed in the clot ^[1]	Repeat testing 2–4 weeks after event, off anticoagulation
Warfarin therapy	Protein S is vitamin K-dependent → warfarin suppresses its synthesis	Withhold warfarin × 2 weeks before testing ^[6]
DOAC therapy	May interfere with functional assays	Withhold DOAC × at least 2 days ^[6]
Liver disease	↓ Hepatic synthesis of Protein S (and Protein C, AT, plus procoagulant factors)	LFT abnormal; other synthetic markers low (albumin, PT prolonged); both procoagulant and anticoagulant factors are low
Vitamin K deficiency / Cholestasis	Vitamin K assists in enzymatic formation of Protein C and S ^[5]; cholestasis → impaired bile secretion → impaired fat absorption → impaired vitamin K absorption	Corrects with parenteral vitamin K; jaundice and ↑ ALP/GGT present
Pregnancy	Levels change in different trimesters ^[1]; ↑ C4BP (acute-phase reactant) → ↓ free Protein S	Do NOT diagnose inherited Protein S deficiency during pregnancy; re-test postpartum
OC pills / HRT	↑ Oestrogen → ↑ C4BP → ↓ free Protein S	Stop OC pills, re-test after washout
Inflammatory states / Infection / Sepsis	C4BP is an acute-phase reactant → rises in inflammation → binds more Protein S → ↓ free Protein S	Concurrent ↑ CRP, ↑ ESR; levels normalise after resolution of inflammation
SLE / Autoimmune disease	Anti-Protein S autoantibodies; also ↑ C4BP in chronic inflammation	Check ANA, anti-dsDNA, complement levels; APLS workup
Nephrotic syndrome	Urinary loss of Protein S	Heavy proteinuria ( > 3.5 g/day), hypoalbuminaemia
DIC	Consumption of all coagulation factors and natural anticoagulants	↑ PT, ↑ APTT, ↓ fibrinogen, ↑ D-dimer, ↓ platelets ^[6]
L-asparaginase therapy	Inhibits hepatic protein synthesis (used in ALL treatment)	Drug history; levels recover after stopping the drug
HIV infection	Possibly autoantibodies or ↓ synthesis	HIV serology

The Golden Rule of Thrombophilia Testing

Do not test at the time of VTE event, or while patients are receiving anticoagulants (withhold warfarin × 2 weeks, DOAC × at least 2 days) ^[6]. Testing during acute thrombosis, on anticoagulants, during pregnancy, or during acute inflammatory states will give falsely low results and lead to misdiagnosis.

A common source of confusion is distinguishing between a patient who clots too much (thrombophilia) and a patient who bleeds too much (coagulopathy). Protein S deficiency causes thrombosis, NOT bleeding — unless the patient is homozygous and develops neonatal purpura fulminans with consumptive coagulopathy (DIC).

Feature	Thrombophilia (e.g. Protein S deficiency)	Coagulopathy (e.g. Haemophilia)
Clinical presentation	DVT, PE, unusual-site thrombosis	Deep-seated bleeding: haemarthrosis, muscle haematoma ^[7]^[14]
PT / APTT	Normal	Prolonged (APTT in haemophilia A/B; PT in Factor VII deficiency)
Platelet count	Normal	Normal (unless DIC or TTP)
Pattern	Venous > > arterial	Mucocutaneous (platelet disorders) vs deep-seated (coagulation disorders) ^[7]
Family history	AD pattern (multiple generations affected, males = females)	X-linked recessive (haemophilia — mainly males) or AD (vWD)

Feature	Protein S Deficiency	Protein C Deficiency	AT III Deficiency	APLS	Malignancy-associated
Inheritance	AD	AD	AD	Acquired	Acquired
Mechanism	↓ Cofactor for APC	↓ APC activity	↓ Thrombin/Xa inactivation	Anti-PL Ab → thrombosis	Tissue factor, mucin, DIC
OR for VTE	~5.4	~7.5	~16.3	Variable	Variable
PT/APTT	Normal	Normal	Normal	APTT often prolonged	Normal or ↑ (if DIC)
Heparin resistance	No	No	Yes	No	No
Warfarin skin necrosis	Possible	Classic	No	No	No
Recurrent miscarriage	Yes	Yes	Yes	Classic	No
Unusual-site VTE	Yes	Yes	Yes	Yes (especially CVA in Chinese SLE ^[10])	Yes (Trousseau)
Lab diagnosis	Free Protein S ↓	Protein C ↓	AT level ↓	Anti-CL, LA, anti-β2GPI	Cancer workup
In Chinese?	Yes	Yes	Yes	Yes	Yes

High Yield Summary — Differential Diagnosis

Two DDx frameworks: (a) DDx of the thrombotic tendency itself; (b) DDx of a low Protein S level on lab testing.
In Hong Kong/Chinese patients, the relevant inherited thrombophilia triad is Protein S, Protein C, and Antithrombin III deficiency. Factor V Leiden and Prothrombin G20210A are NOT found in Chinese ^[4].
Malignancy is the most important cause of unprovoked VTE ^[4] — always exclude before attributing VTE to inherited thrombophilia.
APLS is the most important acquired thrombophilia — characterised by recurrent VTE + pregnancy loss + persistent antiphospholipid antibodies ^[10].
Acquired causes of low Protein S (pregnancy, OC pills, liver disease, acute thrombosis, warfarin, inflammation) are far more common than inherited deficiency and must be excluded before making the diagnosis.
PT and APTT are normal in all three inherited natural anticoagulant deficiencies — you need specific thrombophilia screening assays.
Antithrombin deficiency is the most severe (OR 16.3, heparin resistance); Protein C deficiency has the strongest link to warfarin-induced skin necrosis; Protein S deficiency is the most prevalent (~0.9%).

Active Recall - DDx of Protein S Deficiency

References

^[1] Senior notes: Block A - Leg swelling and chest pain_ deep vein thrombosis; pulmonary embolism; Thrombophilia.pdf (Protein S deficiency section, pp. 10–11) ^[2] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (DVT/PE section, pp. 611–612) ^[3] Senior notes: MBBS Final MB (Surgery) (Felix PY Lai).pdf (DVT/PE section, pp. 964–965) ^[4] Senior notes: Ryan Ho Haemtology.pdf (Thrombophilia screening, p. 135) ^[5] Senior notes: Block A - Introduction to GI_Hepatology investigations (LFT, Endoscopy).pdf (Vitamin K-dependent factors, p. 7) ^[6] Senior notes: Maksim Medicine Notes.pdf (Thrombophilia screening, p. 165) ^[7] Senior notes: Block A - Abnormal bleeding after tooth extraction_ bleeding tendency; thrombocytopenia.pdf (Patterns of bleeding, p. 8) ^[9] Senior notes: Adrian Lui Pediatrics Notes.pdf (Thrombophilia screening, p. 397) ^[10] Senior notes: Ryan Ho Rheumatology.pdf (Antiphospholipid syndrome / Revised Sapporo criteria, p. 73) ^[11] Lecture slides: Respiratory Two cases of acute shortness of breath - case 1.pdf (Predisposing causes of DVT and PE, p. 5) ^[12] Senior notes: learning_points_output.txt (Nephrotic syndrome complications — urinary AT III loss) ^[13] Senior notes: Block A - Splenomegaly_ common causes of splenomegaly; myeloproliferative diseases.pdf (Essential thrombocythaemia, p. 29) ^[14] Senior notes: Block A - Hematology Interactive Tutorial.pdf (Case 2 — pattern of bleeding, p. 5)

Diagnostic Criteria for Protein S Deficiency

Once Protein S deficiency is confirmed, subtyping requires measuring three parameters: total Protein S antigen, free Protein S antigen, and Protein S activity (functional assay).

Three types of Protein S deficiency exist: ^[1]

Type	Total Protein S Antigen	Free Protein S Antigen	Protein S Activity	Interpretation
Type I	↓	↓	↓	Classical quantitative deficiency — less protein made overall
Type II	Normal	Normal	↓	Qualitative (dysfunctional) — normal amount but protein doesn't work properly
Type III	Normal	↓	↓	Normal total but ↑ binding to C4BP → ↓ free (active) fraction

Key insight: Types I and III are now considered allelic — the same PROS1 mutation can present as Type I in youth (low total and free) and Type III later in life (total normalises, free remains low). This is because total Protein S increases with age, potentially masking the underlying deficiency. Type II is the rarest and requires a functional assay to detect.

High Yield Exam Point

When ordering Protein S from the lab, you will receive results in terms of total Protein S and free Protein S → the free form is what we are looking for. ^[1] This is because ~60% of total Protein S is bound to C4BP and is functionally inactive. A patient can have a "normal" total Protein S but still be functionally deficient if free Protein S is low (Type III).

Investigation Modalities

These are ordered for any patient presenting with VTE — they are not specific for Protein S deficiency but establish the clinical context and exclude other diagnoses.

Investigation	Key Findings & Interpretation	Why Order It?
CBC with differential	Should be normal in isolated Protein S deficiency; ↓ platelets → consider DIC, HIT, TTP, APLS; ↑ WBC → infection/malignancy; polycythaemia → MPN	Exclude other haematological causes of thrombosis
PT and APTT	Normal in all three inherited natural anticoagulant deficiencies (Protein S, C, AT) ^[8]^[14]; ↑ PT → liver disease, warfarin, vitamin K deficiency; ↑ APTT → lupus anticoagulant (paradoxically prothrombotic), haemophilia	PT/APTT test thrombin generation, not regulation — Protein S works on the regulatory (anticoagulant) side
Fibrinogen	Normal in Protein S deficiency; ↓ in DIC
D-dimer	Elevated in acute VTE (high sensitivity, low specificity); also elevated in DIC, malignancy, pregnancy, infection, post-surgery ^[8]	D-dimer is quite sensitive → can be used to rule out if a negative test is obtained ^[8] — useful for excluding PE/DVT, not for diagnosing thrombophilia
LFT	If abnormal → liver disease may explain low Protein S (↓ hepatic synthesis); cholestasis with fat malabsorption → impaired vitamin K absorption → ↓ Protein C and S ^[5]	Exclude hepatic cause of acquired Protein S deficiency
RFT, urinalysis	Proteinuria > 3.5 g/day → nephrotic syndrome → urinary loss of Protein S and AT III	Exclude nephrotic syndrome
CRP / ESR	If elevated → acute-phase response → ↑ C4BP → ↓ free Protein S (acquired, not inherited)	Exclude inflammatory cause of falsely low Protein S

Why Are PT and APTT Normal in Protein S Deficiency?

This confuses students. Remember: PT measures the extrinsic pathway (Factor VII → common pathway → thrombin generation) and APTT measures the intrinsic pathway (Factors XII, XI, IX, VIII → common pathway → thrombin generation). Both test how well you make a clot. Protein S doesn't help you make a clot — it helps you stop a clot by inactivating Factors Va and VIIIa through APC. So the "clot-making" tests (PT, APTT) are perfectly normal. You need specific anticoagulant-pathway assays to detect the problem.

B. Specific Thrombophilia Screen

Tests included in a thrombophilia screen: ^[6]

Protein C, Protein S, Activated Protein C Resistance (APCR), Antithrombin (AT)
Factor V Leiden PCR, Prothrombin G20210A mutation
APLS: Anti-cardiolipin, lupus anticoagulant, anti-β2-glycoprotein I antibody (anti-β2 GPI)

Assay	What It Measures	Interpretation
Protein S activity (functional assay)	Measures the actual cofactor function of Protein S in enhancing APC-mediated inactivation of Factor Va	The most important initial test. Uses a clot-based or chromogenic assay. Low activity = functional deficiency regardless of antigen level. Detects all three types (I, II, III)
Free Protein S antigen (immunological)	Quantifies the unbound, free form of Protein S	The free form is what we are looking for ^[1]. Low in Types I and III. Normal in Type II (dysfunctional protein)
Total Protein S antigen (immunological)	Quantifies both free + C4BP-bound Protein S	Low in Type I. Normal in Types II and III. Less clinically useful alone because it includes the inactive bound fraction

Testing algorithm for Protein S subtypes:

Assay	What It Tests	Key Findings
Protein C level (functional + antigenic)	APC activity	Low → Protein C deficiency; associated with warfarin-induced skin necrosis ^[4]
Antithrombin level (functional + antigenic)	AT-III activity	Low → AT deficiency; VTE often resistant to normal doses of heparin ^[4]; OR ~16.3, ~70% have VTE before age 60 ^[4]
Activated Protein C Resistance (APCR)	Screening test for Factor V Leiden	Prolonged APTT fails to further prolong when APC added → resistance; Factor V Leiden NOT found in Chinese ^[4] — abnormal APCR in a Chinese patient may suggest acquired APC resistance (pregnancy, OC pills, APLS)
Factor V Leiden PCR	Confirmatory genetic test	NOT found in Chinese ^[4] — can be omitted in ethnic Chinese patients
Prothrombin G20210A PCR	Prothrombin gain-of-function mutation	Not found in Chinese ^[4]
Lupus anticoagulant (DRVVT — Dilute Russell's Viper Venom Time) ^[8]	Antiphospholipid antibody that prolongs phospholipid-dependent coagulation tests in vitro	Positive → suspect APLS; paradoxically causes thrombosis despite prolonging APTT; use mixing study to differentiate — lupus anticoagulant antibodies immediately destroy healthy plasma phospholipids → inability to correct the APTT ^[8]
Anti-cardiolipin Ab (IgG/IgM)	Antiphospholipid antibody	Moderate to high titre (> 40 units) on ≥ 2 occasions at least 12 weeks apart ^[10]
Anti-β2-glycoprotein I Ab (IgG/IgM)	Antiphospholipid antibody	Same criteria as anti-cardiolipin

GC Lecture Slide Concept — Interpretation of Coagulation Tests

Isolated prolonged APTT: Factor 8 (haemophilia A), Factor 9 (haemophilia B), Factor 11, Factor 12, von Willebrand disease, lupus anticoagulant ^[8]. Isolated prolonged PT: Factor 7 deficiency — drugs, liver disease, warfarin, inherited Factor 7 deficiency ^[8]. In our locality (Hong Kong), the most common cause of isolated prolonged APTT is Factor 12 deficiency (20% prevalence) — does NOT result in bleeding tendency ^[8]. Remember: Protein S deficiency does NOT prolong either PT or APTT — if you see normal PT and APTT in a patient with VTE, that is entirely consistent with thrombophilia.

Investigation	When to Use	Key Points
Repeat Protein S testing (≥ 6–12 weeks later)	Always required	A single low result is insufficient — must confirm persistence. If the second test also shows low free Protein S with no acquired cause → inherited deficiency confirmed
PROS1 genetic testing	When phenotypic diagnosis is equivocal; for family screening; for pre-conception counselling	Identifies specific mutations in the PROS1 gene on chromosome 3q11.1 ^[4]; over 200 mutations described; note there is a pseudogene (PROSP) nearby that complicates PCR — requires careful assay design
Family screening	First-degree relatives of confirmed cases	Supports autosomal dominant inheritance pattern; identifies at-risk family members who may benefit from prophylaxis in high-risk situations (pregnancy, surgery)

When a patient presents with VTE and you suspect Protein S deficiency as the underlying cause, you also need to confirm the VTE itself:

Investigation	For DVT	For PE
Compression ultrasound	First-line for DVT diagnosis; loss of compressibility of deep vein = positive	Not applicable
D-dimer	High negative predictive value — can be used to rule out if a negative test is obtained ^[8]; if low pre-test probability + negative D-dimer → DVT excluded	Same principle for PE
CT pulmonary angiography (CTPA)	Not applicable	Gold standard for PE diagnosis; directly visualises filling defects in pulmonary arteries
V/Q scan	Not applicable	Alternative to CTPA when CT contraindicated (renal impairment, contrast allergy); mismatch = perfusion defect with preserved ventilation
Echocardiography	Not applicable	Assesses RV strain in massive PE; RV dilation, tricuspid regurgitation, McConnell's sign
CT venography	Can be added to CTPA to simultaneously assess LL veins	Combined CT for PE + DVT

This is a critical step — performing this is what separates a careful clinician from one who over-diagnoses inherited thrombophilia.

Investigation	Acquired Cause Being Excluded	Expected Finding if This is the Cause
LFT (albumin, bilirubin, ALT, ALP, GGT)	Liver disease, cholestasis	↓ Albumin, ↑ bilirubin, ↑ transaminases or cholestatic enzymes
PT after vitamin K trial	Vitamin K deficiency / cholestasis	If PT corrects with parenteral vitamin K → vitamin K deficiency, not hepatocellular failure ^[5]
Pregnancy test (β-hCG)	Pregnancy	Positive → Protein S physiologically drops; do not diagnose inherited deficiency
Drug history	Warfarin, DOACs, OC pills, HRT, L-asparaginase	Temporal relationship with medication use
CRP, ESR	Inflammatory states	↑ CRP/ESR → C4BP rises (acute-phase reactant) → ↓ free Protein S
Urinalysis + urine protein/creatinine ratio	Nephrotic syndrome	> 3.5 g/day proteinuria, hypoalbuminaemia, oedema
HIV serology	HIV infection	If positive → acquired cause identified
ANA, anti-dsDNA, complement levels	SLE	If positive → consider SLE-related acquired Protein S deficiency or secondary APLS

Pitfall	Explanation
Testing during acute VTE	All three natural anticoagulants are consumed in the clot ^[1] → falsely low → wait 2–4 weeks
Testing while on warfarin	Protein S is vitamin K-dependent → warfarin reduces synthesis → falsely low; withhold warfarin × 2 weeks ^[6]
Testing while on DOAC	DOACs interfere with clot-based functional assays → withhold DOAC × at least 2 days ^[6]
Testing during pregnancy	Protein S levels change in different trimesters ^[1]; physiologically ↓ free Protein S due to ↑ C4BP
Relying on total Protein S alone	Total Protein S can be normal in Type III deficiency; free Protein S is what we are looking for ^[1]
Diagnosing on a single low result	Must confirm with repeat testing — many transient acquired causes
Forgetting to screen the family	Inherited = autosomal dominant → should test first-degree relatives
Confusing APCR with Protein S deficiency	APCR tests for Factor V Leiden (resistance to APC) — a different mechanism; both result in impaired APC pathway but at different levels

Distinguishing Protein C from Protein S Deficiency on Lab Testing

Both cause a low APC pathway activity. The key is which specific assay is low:

Low Protein C level → Protein C deficiency
Low free Protein S level → Protein S deficiency
Both can be low simultaneously in liver disease, warfarin use, vitamin K deficiency, or DIC (acquired, not inherited)
If both are low with no acquired cause → consider compound heterozygosity (extremely rare) or re-test after longer washout

Category	Tests	Key Interpretation
Baseline coagulation	PT, APTT, fibrinogen, D-dimer	Normal PT and APTT in Protein S deficiency
Protein S-specific	Free Protein S activity, free Protein S antigen, total Protein S antigen	Free Protein S is the key — low activity is the primary diagnostic finding
Full thrombophilia panel	Protein C, AT level, APCR, Factor V Leiden PCR, APLS panel ^[6]	Distinguish from other inherited/acquired thrombophilias
Acquired cause exclusion	LFT, RFT, urinalysis, CRP/ESR, pregnancy test, drug history, HIV, ANA	Must be negative before diagnosing inherited
Confirmatory	Repeat Protein S ≥ 6–12 weeks, PROS1 genetic testing, family screening	Persistence + family concordance = inherited
VTE confirmation	Compression USS (DVT), CTPA (PE), D-dimer	Confirm the thrombotic event

High Yield Summary — Diagnosis

No formal diagnostic criteria exist — diagnosis is clinical + laboratory + exclusion of acquired causes + confirmation on repeat testing.
Free Protein S (activity and antigen) is the key measurement — not total Protein S ^[1].
Three types (I: ↓ total + ↓ free; II: normal total + normal free but ↓ activity; III: normal total + ↓ free) ^[1].
Timing is everything: do not test during acute VTE, on warfarin (withhold 2 weeks), on DOAC (withhold 2 days), during pregnancy, or during acute inflammation ^[1]^[6].
PT and APTT are normal — these test thrombin generation, not regulation.
Must exclude acquired causes (liver disease, vitamin K deficiency, pregnancy, OC pills, inflammation, nephrotic syndrome, DIC) before diagnosing inherited.
Confirm with repeat testing ≥ 6–12 weeks later and screen first-degree relatives.
Full thrombophilia panel includes: Protein C, Protein S, AT, APCR, Factor V Leiden PCR, Prothrombin G20210A, APLS panel ^[6].
In Hong Kong: skip Factor V Leiden and Prothrombin G20210A PCR in ethnic Chinese ^[4].

Active Recall - Diagnosis of Protein S Deficiency

Management of Protein S Deficiency

A. Acute VTE Treatment

When a patient with known or newly-diagnosed Protein S deficiency presents with acute DVT or PE, the management follows standard VTE treatment protocols — with important caveats specific to thrombophilia.

Agent	Dose / Route	Mechanism	Key Points
LMWH (e.g. enoxaparin)	1 mg/kg SC BD (therapeutic dose) or 1.5 mg/kg SC OD	Potentiates Antithrombin III → inactivates Factor Xa (predominantly) and thrombin	First-line for initial treatment; predictable pharmacokinetics; does not require routine monitoring (except in renal impairment, obesity, pregnancy)
UFH (unfractionated heparin)	IV bolus 5000 IU → continuous infusion, titrated to APTT 2–2.5× control ^[15]	Potentiates Antithrombin III → inactivates thrombin and Factor Xa equally	Preferred in massive PE (may need thrombolysis), renal impairment (no renal clearance), or when rapid reversibility needed (short half-life ~1 h, reversed by protamine)
Fondaparinux	7.5 mg SC OD (weight-based)	Selective Factor Xa inhibitor via AT-III	Alternative if heparin contraindicated (e.g. HIT history)

Why Not Start Warfarin Alone?

Warfarin should NEVER be started as the sole anticoagulant from day 1 in Protein S deficiency. Warfarin inhibits synthesis of vitamin K-dependent factors — but Protein C (half-life ~8 h) and Protein S (half-life ~36–60 h) drop faster than the procoagulant factors (Factor II half-life ~60 h, Factor X ~36 h). In a patient already deficient in Protein S, this creates a catastrophic transient hypercoagulable state → warfarin-induced skin necrosis ^[4]^[16]. Always bridge with heparin (LMWH or UFH) for at least 5 days AND until INR is therapeutic for ≥ 24 h before stopping heparin.

Agent	Mechanism	Monitoring	Key Considerations for Protein S Deficiency
Warfarin (vitamin K antagonist)	Inhibits VKORC1 → ↓ synthesis of Factors II, VII, IX, X and Protein C, S	INR target 2.0–3.0	Must always bridge with heparin; risk of skin necrosis; start at low dose (e.g. 5 mg, not loading dose); interacts with many drugs and foods; TTR (time in therapeutic range) is critical — better outcomes when more time spent in range ^[16]
DOACs (Direct Oral Anticoagulants)	Rivaroxaban, apixaban (Factor Xa inhibitors); dabigatran (direct thrombin inhibitor)	No routine monitoring; adjust for renal function	Increasingly used as alternative to warfarin in inherited thrombophilia; no risk of skin necrosis (do not affect Protein C/S synthesis); fixed dosing; fewer drug-food interactions; contraindicated in pregnancy (teratogenic); evidence in inherited thrombophilia still growing but current guidelines accept their use

Practical note on DOACs in Protein S deficiency: DOACs are now widely accepted for VTE treatment in patients with inherited thrombophilia (excluding APLS, where DOACs are inferior to warfarin — TRAPS trial). For Protein S deficiency specifically, DOACs have the major advantage of avoiding warfarin-induced skin necrosis entirely. However, monitoring thrombophilia levels on DOACs requires drug washout (recall: withhold DOAC × at least 2 days ^[6] before testing).

Intervention	Indication	Key Points
Systemic thrombolysis (rtPA/alteplase)	Massive PE with haemodynamic instability (SBP < 90 mmHg / obstructive shock)	Absolute contraindications: prior ICH, active bleeding, suspected aortic dissection ^[17]; relative contraindications include recent surgery, pregnancy, active peptic ulcer, current anticoagulant use
Catheter-directed thrombolysis	Sub-massive PE or when systemic thrombolysis contraindicated	Lower systemic bleeding risk
Surgical embolectomy	Massive PE with contraindication to thrombolysis or failed thrombolysis	Rare; requires cardiothoracic surgery capability
IVC filter	Absolute contraindication to anticoagulation, or recurrent PE despite adequate anticoagulation	Retrievable filters preferred; does not treat the underlying thrombophilia — only prevents embolisation

This is the most nuanced aspect of managing Protein S deficiency. The decision framework:

Scenario	Recommended Duration	Rationale
First provoked VTE (clear trigger: surgery, immobilisation, OC pills)	3–6 months, then reassess	Provocation was the primary driver; inherited deficiency is a background risk factor; removing the provocation may be sufficient
First unprovoked VTE	Individualise decision for indefinite anticoagulation ^[4] — lean toward indefinite if no high bleeding risk	Unprovoked VTE in a patient with inherited thrombophilia has a higher recurrence rate (~10%/year without anticoagulation vs ~3%/year general population)
Recurrent VTE	Indefinite anticoagulation	High recurrence risk clearly outweighs bleeding risk
Life-threatening VTE (massive PE, CVST)	Indefinite anticoagulation	Severity of initial event justifies lifelong protection
Unusual-site thrombosis	Indefinite anticoagulation — strong consideration	Unusual sites (mesenteric, portal, cerebral venous sinus) suggest a more aggressive thrombophilic phenotype
Combined thrombophilia (Protein S deficiency + another defect)	Indefinite anticoagulation	Multiplicative risk

High Yield – Protein S vs Protein C: Duration of Anticoagulation

Protein C deficiency: anticoagulation in VTE → should continue indefinitely ^[4]. Protein S deficiency: anticoagulation in VTE → individualise decision for indefinite anticoagulation ^[4]. This difference reflects the slightly lower thrombotic risk of Protein S deficiency (OR ~5.4 vs ~7.5 for Protein C). In practice, many haematologists still lean toward indefinite therapy for unprovoked VTE in Protein S deficiency, but the decision involves shared decision-making considering bleeding risk, patient preference, and compliance.

Factor	Why
Unprovoked or recurrent VTE	Higher recurrence risk without anticoagulation
Male sex	Males have ~1.5× higher VTE recurrence risk than females
Elevated D-dimer 1 month after stopping anticoagulation	Suggests ongoing thrombotic tendency
Post-thrombotic syndrome (residual venous obstruction on ultrasound)	Damaged veins predispose to recurrence
Combined thrombophilia	Multiplicative risk
Low bleeding risk (young, no comorbidities, no anaemia, no falls risk)	Favourable risk-benefit ratio

Factor	Why
Clearly provoked first VTE	Removing provocation may be sufficient
High bleeding risk (elderly, falls, anaemia, thrombocytopenia, concurrent antiplatelet, renal failure)	Bleeding risk outweighs recurrence risk
Patient preference after informed discussion	Shared decision-making
Female with hormone-related provocation (OC pills) who discontinues the hormone	Removing the second hit

C. Prophylaxis in High-Risk Situations (Asymptomatic Carriers or Post-VTE Patients)

This is the management of patients who carry the Protein S deficiency genotype but have not yet had a VTE event, or who have completed their acute treatment course and are now in a stable state.

Prophylactic anticoagulation in pregnancy, surgery ^[4] is recommended for all patients with known Protein S deficiency.

Situation	Regimen	Notes
Minor surgery (low VTE risk)	Mechanical prophylaxis (graduated compression stockings, intermittent pneumatic compression) ± prophylactic LMWH	Mobilise early
Major surgery (high VTE risk)	Prophylactic LMWH (e.g. enoxaparin 40 mg SC OD, or weight-adjusted)	Start 6–12 h pre-op or 6–12 h post-op; continue until fully mobile or for ≥ 7–14 days post-op
Perioperative management of patients already on warfarin	Stop warfarin 5 days before operation if INR 2–3; bridging with LMWH when INR becomes subtherapeutic; discontinue LMWH 12 h before OT ^[16]	Indications for LMWH bridging include known hypercoagulability e.g. Protein C/S deficiency ^[16] — this is a high-yield perioperative medicine point

Perioperative Bridging — GC/Surgery Key Point

Known hypercoagulability e.g. protein C/S deficiency is listed as an indication for perioperative LMWH bridging when interrupting warfarin for surgery ^[16]. This means Protein S-deficient patients on warfarin should NOT simply stop their warfarin before surgery without heparin cover — they need bridging to prevent perioperative VTE.

Pregnancy in Protein S deficiency is high-risk and requires a coordinated approach between haematology and obstetrics.

Phase	Regimen	Rationale
Antepartum	LMWH throughout pregnancy (prophylactic or therapeutic dose depending on VTE history)	Warfarin is contraindicated in pregnancy — crosses placenta → risk of fetal ICH and teratogenicity ^[4]; DOACs are also contraindicated (insufficient safety data, animal teratogenicity); LMWH does not cross placenta
Peripartum	Stop LMWH ≥ 12 h before planned delivery (24 h for therapeutic dose)	Reduce bleeding risk during delivery
Postpartum	Continue LMWH (or transition to warfarin) for ≥ 6 weeks postpartum ^[4]	Puerperium is the highest-risk period — blood returns from contracted uterus, hypercoagulable state peaks; warfarin is safe in breastfeeding

Why LMWH in Pregnancy?

Warfarin crosses the placenta ^[4]. In the first trimester, it causes warfarin embryopathy (nasal hypoplasia, stippled epiphyses — disrupts vitamin K-dependent bone formation). Later, it causes fetal ICH (fetus has immature liver → cannot handle anticoagulant effect). LMWH is a large molecule that does NOT cross the placenta → safe for the fetus. DOACs also cross the placenta and are teratogenic in animal studies → contraindicated.

Situation	Advice
Long-haul flights ( > 4–6 h)	Hydration, leg exercises, aisle seat; graduated compression stockings; consider single prophylactic LMWH dose for very long flights
Prolonged immobilisation (hospitalisation)	Prophylactic LMWH + mechanical prophylaxis (compression stockings or intermittent pneumatic compression)

Intervention	Rationale
Avoid combined oral contraceptive pills	High-dose oestrogen → ↑ coagulation factor production ^[4] AND ↑ C4BP → ↓ free Protein S; use progesterone-only contraception, IUD, or barrier methods instead
Avoid HRT with oestrogen	Same mechanism as OC pills
Smoking cessation	Endothelial dysfunction adds to thrombotic risk
Weight management	Obesity increases venous stasis and chronic inflammation
Avoid dehydration	Dehydration increases blood viscosity → stasis
Active lifestyle	Regular exercise promotes venous return

E. Management of Special Situations

Step	Action
Stop warfarin immediately	Remove the cause
Start therapeutic heparin (LMWH or UFH)	Provide anticoagulation while Protein C/S levels recover
Protein C concentrate (if available) or FFP	Replenish Protein C/S; FFP contains all soluble plasma proteins and clotting factors ^[18]
Vitamin K	May help restore Protein C/S synthesis (both are vitamin K-dependent)
Wound care + surgical debridement if necessary	Necrotic skin may require grafting
Future anticoagulation: switch to DOAC	DOACs do not affect Protein C/S synthesis → no risk of recurrence; alternatively, if warfarin must be restarted, do so at very low dose with prolonged heparin overlap

Treatment	Rationale
Protein S concentrate (if available) or FFP	Replace absent Protein S; FFP also provides Protein C and AT
Therapeutic heparin	Anticoagulate while replacing the deficient factor
Supportive care (NICU)	Manage DIC, multi-organ failure
Long-term: lifelong anticoagulation + consideration of liver transplant	Liver transplant provides a source of normal Protein S synthesis

Approach	Details
Pre-conception counselling	Assess thrombotic risk; plan LMWH regimen
Prophylactic or therapeutic LMWH throughout pregnancy	Prevents placental microvascular thrombosis
Low-dose aspirin (75–150 mg OD)	May improve placental blood flow; often combined with LMWH in women with recurrent pregnancy loss and thrombophilia (evidence stronger for APLS, extrapolated for Protein S deficiency)
Close obstetric monitoring	Serial growth scans, uterine artery Doppler

Action	Details
Screen first-degree relatives	Protein S functional assay + free Protein S antigen; identify asymptomatic carriers who may benefit from prophylaxis in high-risk situations
Genetic counselling	Autosomal dominant ^[1] → 50% chance of transmission to each offspring; discuss implications for pregnancy, surgery, contraception
PROS1 genetic testing	Confirm specific mutation; useful for predictive testing in family members
Pre-conception counselling for female carriers	Discuss pregnancy risks, contraception choices (avoid OC pills), LMWH use in pregnancy

Feature	Protein S Deficiency	Protein C Deficiency	AT III Deficiency
Initial VTE treatment	LMWH/UFH → transition to warfarin or DOAC	Same	Higher dose LMWH (≥ 100 U/kg/d); AT concentrate if refractory ^[4]
Duration	Individualise for indefinite ^[4]	Indefinite ^[4]	Prophylaxis in pregnancy, surgery or post-VTE ^[4]; strong tendency toward indefinite
Warfarin use	Caution — bridge with heparin	Extra caution — highest risk of skin necrosis ^[4]	No specific warfarin concern (AT is not vitamin K-dependent)
Heparin response	Normal	Normal	May be resistant to normal heparin doses ^[4] — heparin works BY potentiating AT-III
Pregnancy	LMWH throughout + 6 weeks postpartum	Same	Same + may need AT concentrate
DOAC use	Acceptable alternative	Acceptable alternative	Acceptable alternative

Drug	Mechanism	Indication in Protein S Deficiency	Contraindications	Key Side Effects
Enoxaparin (LMWH)	Potentiates AT-III → predominantly anti-Xa	Acute VTE treatment; surgical/pregnancy prophylaxis	Active major bleeding; HIT; severe renal impairment (use UFH instead)	Bleeding; HIT (rare with LMWH); injection site reactions; osteoporosis (long-term)
UFH	Potentiates AT-III → anti-thrombin + anti-Xa equally	Massive PE; renal failure; need for rapid reversibility	Active major bleeding; HIT	Bleeding; HIT (more common than LMWH); osteoporosis
Warfarin	Inhibits VKORC1 → ↓ Factors II, VII, IX, X and Protein C, S	Long-term anticoagulation after VTE	Pregnancy (teratogenic) ^[4]; active bleeding; never start without heparin bridging in Protein S deficiency	Warfarin-induced skin necrosis; bleeding; drug/food interactions; requires INR monitoring
Rivaroxaban / Apixaban (DOACs — Factor Xa inhibitors)	Direct Factor Xa inhibition	Long-term anticoagulation; avoids warfarin skin necrosis risk	Pregnancy; severe renal impairment (varies by agent); active bleeding; mechanical heart valves; APLS	Bleeding; GI upset (rivaroxaban); no routine monitoring needed but no reliable reversal for apixaban (andexanet alfa limited availability)
Dabigatran (DOAC — direct thrombin inhibitor)	Direct thrombin inhibition	Alternative long-term anticoagulation	Pregnancy; severe renal impairment (renally cleared); mechanical heart valves; APLS	Bleeding; dyspepsia; reversed by idarucizumab ^[16]
Alteplase (rtPA)	Activates plasminogen → plasmin → fibrin clot lysis	Massive PE with haemodynamic instability	Prior ICH; active bleeding; suspected aortic dissection; recent stroke < 3 months ^[17]	Major haemorrhage (including ICH)
Protein C concentrate / FFP	Replaces deficient natural anticoagulants	Warfarin-induced skin necrosis; neonatal purpura fulminans	Volume overload (FFP); allergic reactions	Transfusion reactions; volume overload

High Yield Summary — Management

Acute VTE: Start LMWH or UFH → transition to warfarin (with heparin bridge) or DOAC. Never start warfarin alone — risk of skin necrosis ^[4].
Duration: Protein S deficiency — individualise decision for indefinite anticoagulation ^[4]. Favour indefinite if unprovoked, recurrent, or life-threatening VTE.
Prophylaxis: Prophylactic anticoagulation in pregnancy, surgery ^[4] for all known carriers. Known hypercoagulability is an indication for perioperative LMWH bridging ^[16].
Pregnancy: LMWH throughout pregnancy + ≥ 6 weeks postpartum. Warfarin contraindicated (crosses placenta). DOACs contraindicated.
Lifestyle: Avoid OC pills (↑ oestrogen → ↓ free Protein S + ↑ procoagulant factors). Use progesterone-only or non-hormonal contraception.
Family: Screen first-degree relatives; genetic counselling for autosomal dominant inheritance.
AT deficiency is different: may need higher dose LMWH and AT concentrate because heparin requires AT-III to work ^[4].

Active Recall - Management of Protein S Deficiency

References

^[1] Senior notes: Block A - Leg swelling and chest pain_ deep vein thrombosis; pulmonary embolism; Thrombophilia.pdf (Protein S deficiency section, pp. 10–11) ^[4] Senior notes: Ryan Ho Haemtology.pdf (Thrombophilia screening and inherited thrombophilia management, pp. 132, 135) ^[6] Senior notes: Maksim Medicine Notes.pdf (Thrombophilia screening, p. 165) ^[15] Senior notes: MBBS Final MB (Surgery) (Felix PY Lai).pdf (Acute arterial ischaemia — heparin dosing, p. 926) ^[16] Senior notes: Maksim Surgery Notes.pdf (Perioperative warfarin management and bridging indications, pp. 25–26) ^[17] Senior notes: Block A - Sudden severe chest pain_ acute myocardial infarction; aortic dissection.pdf (Thrombolysis contraindications, p. 20) ^[18] Senior notes: Ryan Ho Haemtology.pdf (FFP indications and blood products, p. 144)

Complications of Protein S Deficiency

The complications of Protein S deficiency arise from two sources:

The thrombophilic state itself → thrombotic complications
The treatment (anticoagulation) → bleeding complications and drug-specific adverse effects

Think of it this way: Protein S deficiency shifts the haemostatic balance toward clotting. The complications are the downstream consequences of that clotting tendency, plus the iatrogenic consequences of the anticoagulants we use to counteract it.

PE is the most feared acute complication of Protein S deficiency. It occurs when a DVT (usually from the lower limbs) embolises to the pulmonary vasculature.

Severity	Mechanism	Clinical Consequence
Minor/Subsegmental PE	Small emboli lodge in distal pulmonary arteries	May be subclinical or cause pleuritic chest pain, mild dyspnoea; pulmonary infarction → haemoptysis
Submassive PE	Moderate-sized emboli → RV strain without systemic hypotension	Tachycardia, dyspnoea, elevated troponin/BNP, RV dilation on echo; significant morbidity
Massive PE	Large saddle embolus or bilateral main PA emboli → acute RV outflow obstruction	Obstructive shock (SBP < 90 mmHg), syncope, cardiac arrest; patients with PE usually die from right heart failure (cardiogenic shock) rather than hypoxaemia ^[2]

Long-term consequence: Recurrent PE (even subclinical) can lead to chronic thromboembolic pulmonary hypertension (CTEPH) — irreversible remodelling of the pulmonary vasculature.

High Yield – Why PE Kills

The lethal mechanism of massive PE is obstructive shock, not hypoxaemia. The massive embolus obstructs the pulmonary outflow tract → the right ventricle cannot eject blood into the pulmonary circulation → ↓ LV preload → ↓ cardiac output → systemic hypoperfusion → death. This is why echocardiography showing RV dilation is so important in risk-stratifying PE.

Protein S deficiency is one of the inherited thrombophilias that predispose to thrombosis in unusual venous territories. These are more dangerous because they are harder to diagnose and may present with non-specific symptoms.

Site	Clinical Consequence	Pathophysiological Basis
Cerebral Venous Sinus Thrombosis (CVST)	Ischaemic stroke can arise from hypercoagulability: protein C/S deficiency ^[20]; headache, seizures, focal deficits, raised ICP, venous infarction ± haemorrhagic transformation	Thrombosis of the dural sinuses (superior sagittal, transverse, sigmoid) → impaired venous drainage → venous congestion → cerebral oedema and infarction
Mesenteric Vein Thrombosis	Abdominal pain (out of proportion to exam), bloody diarrhoea, bowel ischaemia → infarction	Thrombosis of superior or inferior mesenteric veins → impaired venous drainage of small/large bowel → haemorrhagic infarction of bowel wall
Portal Vein Thrombosis	May be clinically silent or present with abdominal pain; when chronic → cavernous transformation, development of collaterals: increase in variceal bleeding, increase in ascites ^[21]	Thrombosis of portal vein → portal hypertension (pre-hepatic); if Protein S-deficient patient also has cirrhosis, this compounds the intra-hepatic portal hypertension
Renal Vein Thrombosis	Flank pain, haematuria, proteinuria, acute kidney injury; hypercoagulability of nephrotic syndrome involves urinary loss of antithrombotic factors such as antithrombin III and Protein S ^[22] — creating a "double hit" if patient has both nephrotic syndrome and inherited Protein S deficiency	Thrombosis of renal veins → venous congestion of kidney → ↓ GFR; particularly common in membranous nephropathy
Hepatic Vein Thrombosis (Budd-Chiari Syndrome)	Acute: hepatomegaly, ascites, abdominal pain; chronic: cirrhosis, portal hypertension	Thrombosis of hepatic veins → impaired hepatic venous outflow → sinusoidal congestion → hepatocellular damage

These are critically important in young women with Protein S deficiency.

Complication	Mechanism
Recurrent pregnancy loss (especially 2nd/3rd trimester)	Placental microvascular thrombosis → placental insufficiency → fetal hypoxia → miscarriage/stillbirth; thrombosis of the intervillous space and spiral arterioles
Intrauterine growth restriction (IUGR)	Chronic placental insufficiency from subclinical microvascular thrombosis → reduced nutrient/oxygen delivery to fetus
Pre-eclampsia	Placental ischaemia (from microvascular thrombosis) → release of anti-angiogenic factors (sFlt-1, sEng) → maternal endothelial dysfunction → hypertension + proteinuria
Placental abruption	Thrombosis of decidual vessels → retroplacental haemorrhage → premature placental separation
Stillbirth	Severe placental insufficiency or acute placental vessel thrombosis
Maternal VTE (DVT/PE)	Pregnancy is a hypercoagulable state due to ↑ coagulation factor production and ↑ venous stasis ^[4]; Protein S deficiency on top of physiological pregnancy hypercoagulability → high risk, especially in 3rd trimester and puerperium

This is a complication that is specifically associated with Protein C/S deficiency and occurs as a direct consequence of inappropriate warfarin initiation.

Feature	Details
Timing	Days 3–5 of warfarin initiation
Mechanism	Warfarin suppresses all vitamin K-dependent factors. Protein C (half-life ~8 h) and Protein S (half-life ~36–60 h) fall faster than procoagulant factors (Factor II half-life ~60 h) → transient hypercoagulable state → microvascular thrombosis in dermal and subcutaneous vessels
Clinical features	Painful erythematous patches → haemorrhagic bullae → black necrotic eschar; typically in fatty areas (breasts, buttocks, thighs, abdomen)
Risk factors	Protein C deficiency (classic association — warfarin-induced skin necrosis ^[4]); Protein S deficiency; starting warfarin at high loading dose without heparin bridging
Prevention	Always bridge with heparin (LMWH or UFH) when starting warfarin in patients with known or suspected Protein C/S deficiency; start warfarin at low dose (≤ 5 mg); do not stop heparin until INR is therapeutic for ≥ 24 h
Treatment	Stop warfarin; start therapeutic heparin; Protein C concentrate or FFP; wound care ± surgical debridement; consider switching to DOAC for long-term anticoagulation

Why Fatty Areas?

The skin necrosis preferentially affects fat-rich areas (breasts, buttocks, thighs) because the subcutaneous fat microvasculature has relatively low blood flow → more susceptible to thrombosis when the anticoagulant-procoagulant balance tips toward clotting. The microvascular thrombosis occludes end-arterioles in the subcutaneous fat → ischaemic necrosis of the overlying skin.

This is the most severe complication of Protein S deficiency, occurring in homozygous or compound heterozygous neonates who have near-absent Protein S activity.

Feature	Details
Timing	Hours to days after birth
Mechanism	Complete absence of Protein S → no APC cofactor activity → unopposed Factor Va/VIIIa → massive uncontrolled thrombin generation → widespread microvascular thrombosis → DIC
Clinical features	Widespread purpuric skin lesions rapidly progressing to necrosis; DIC with consumptive coagulopathy (oozing, petechiae, bleeding from puncture sites); purpura fulminans: due to protein C deficiency ^[6] — same mechanism applies to Protein S deficiency (both work on the same APC pathway); multi-organ failure
Mortality	Extremely high without immediate treatment
Treatment	Protein S concentrate or FFP (to replace Protein S); therapeutic heparin; supportive NICU care; long-term: lifelong anticoagulation ± liver transplant

PTS is the chronic sequela of DVT and is relevant because Protein S deficiency patients may have recurrent DVTs, each episode compounding the venous damage.

Feature	Pathophysiological Basis
Chronic leg swelling	DVT damages venous valves → chronic venous insufficiency → persistent ambulatory venous hypertension → oedema
Pain and heaviness	Chronic venous congestion → tissue hypoxia and inflammation
Skin changes: hyperpigmentation	Chronic venous hypertension → extravasation of RBCs into interstitial tissue → haemoglobin degradation → haemosiderin deposition (brown pigmentation, especially at medial malleolus)
Lipodermatosclerosis	Chronic inflammation + fibrosis of subcutaneous fat → woody induration of the skin
Varicose eczema	Chronic venous hypertension → inflammatory dermatitis
Venous ulcers (medial malleolus)	End-stage chronic venous insufficiency → tissue breakdown in the area of highest venous pressure (medial ankle)

Prevention of PTS:

Graduated compression stockings (GCS) — worn daily for ≥ 2 years after DVT (though evidence from the SOX trial questions their efficacy, they remain commonly recommended)
Adequate initial anticoagulation to minimise clot burden
Early mobilisation

CTEPH is a long-term complication of recurrent PE. It develops in ~2–4% of patients after symptomatic PE.

Feature	Mechanism
Definition	Pulmonary hypertension (mPAP ≥ 20 mmHg) caused by organised thromboembolic material in pulmonary arteries, persisting ≥ 3 months after acute PE despite adequate anticoagulation
Pathogenesis	Unresolved thromboembolic material → chronic obstruction of pulmonary arteries → secondary vascular remodelling (intimal fibrosis, medial hypertrophy) → ↑ pulmonary vascular resistance → RV pressure overload → RV failure
Clinical features	Progressive exertional dyspnoea, exercise intolerance, syncope, signs of RV failure (elevated JVP, peripheral oedema, hepatomegaly)
Diagnosis	V/Q scan (mismatched perfusion defects); CTPA; right heart catheterisation; pulmonary angiography
Treatment	Pulmonary endarterectomy (surgical — potentially curative); balloon pulmonary angioplasty (for inoperable disease); riociguat (soluble guanylate cyclase stimulator); lifelong anticoagulation

These complications are not specific to Protein S deficiency but affect all patients on long-term anticoagulation.

Complication	Mechanism	Risk Factors	Management
Major bleeding (GI, intracranial, retroperitoneal)	Anticoagulants impair haemostasis → inability to form adequate clots at sites of vascular injury	Age > 65, renal impairment, concurrent antiplatelet use, recent surgery, falls risk, history of GI bleeding, uncontrolled hypertension	Stop anticoagulant; reversal agents (vitamin K for warfarin; idarucizumab for dabigatran ^[16]; andexanet alfa for anti-Xa DOACs; protamine for heparin); FFP/PCC; supportive care
Heparin-Induced Thrombocytopenia (HIT)	Heparin-PF4 complex → autoantibodies → platelet activation → paradoxical thrombosis + thrombocytopenia	Typically day 5–14 of heparin exposure; more common with UFH than LMWH	Stop ALL heparin; start non-heparin anticoagulant (argatroban, bivalirudin, fondaparinux); do NOT give warfarin until platelets recover ( > 150); confirmatory testing: anti-PF4/heparin ELISA, SRA
Osteoporosis (long-term heparin)	Heparin inhibits osteoblast function and promotes osteoclast activity	Long-term LMWH use (e.g. throughout pregnancy)	Monitor bone density; calcium/vitamin D supplementation; consider switching to DOAC postpartum
Warfarin drug/food interactions	30% of warfarin response can be attributed to genetic variation in pharmacokinetic and pharmacodynamic differences ^[23]; CYP2C9 and VKORC1 polymorphisms; cytochrome P450 inducers/inhibitors; vitamin K-rich foods	Polypharmacy; variable diet; genetic CYP2C9/VKORC1 variants	Careful INR monitoring; patient education about consistent vitamin K intake; pharmacogenomic-guided dosing where available
Warfarin embryopathy (if used in pregnancy)	Warfarin crosses placenta → risk of fetal ICH and teratogenicity ^[4]; disrupts vitamin K-dependent bone proteins → nasal hypoplasia, stippled epiphyses (1st trimester); fetal ICH (any trimester)	Use during pregnancy, especially 6–12 weeks gestation	Avoid warfarin in pregnancy; use LMWH throughout
DOAC-related GI side effects	Rivaroxaban: upper GI bleeding (acidic drug formulation); dabigatran: dyspepsia (tartaric acid core)	Concurrent NSAID/antiplatelet use; GI pathology	Take rivaroxaban with food; consider apixaban (lower GI bleeding risk); avoid concurrent NSAIDs

Often underappreciated but significant, particularly for young patients with a lifelong condition:

Complication	Impact
Anxiety about thrombotic events	Living with the knowledge of a hereditary thrombophilia causes chronic health anxiety, especially around surgery, travel, and pregnancy
Impact on reproductive choices	Need for LMWH injections throughout pregnancy; genetic counselling regarding 50% transmission risk; avoidance of OC pills limits contraceptive options
Lifestyle restrictions	Avoidance of prolonged immobility, need for travel precautions, need for medical alert identification
Anticoagulation burden	Warfarin: frequent INR monitoring, dietary restrictions, drug interactions; LMWH: daily injections, injection site bruising; DOACs: cost, limited reversal agents
Insurance and occupational implications	Potential difficulty obtaining life/travel insurance; may affect certain occupations

Category	Complication	Mechanism	Prevention/Management
Acute thrombotic	DVT	↓ Protein S → ↓ APC function → unregulated thrombin generation	Anticoagulation
	PE	Embolisation from DVT	Anticoagulation; thrombolysis if massive
	CVST, mesenteric/portal/renal vein thrombosis	Unusual-site thrombosis	Anticoagulation; maintain high clinical suspicion
Chronic thrombotic	Post-thrombotic syndrome	Valve damage from DVT	Compression stockings; adequate initial anticoagulation
	CTEPH	Unresolved PE → pulmonary vascular remodelling	Lifelong anticoagulation; pulmonary endarterectomy
Obstetric	Recurrent pregnancy loss, IUGR, pre-eclampsia, abruption	Placental microvascular thrombosis	LMWH + low-dose aspirin in pregnancy
Iatrogenic	Warfarin-induced skin necrosis	Rapid Protein C/S depletion without heparin bridging	Always bridge with heparin; low warfarin starting dose
	Neonatal purpura fulminans	Homozygous deficiency → DIC	Protein S concentrate/FFP + heparin
Treatment-related	Major bleeding, HIT, osteoporosis, warfarin embryopathy	Anticoagulant adverse effects	Reversal agents; dose adjustment; avoid warfarin in pregnancy

High Yield Summary — Complications

DVT and PE are the cardinal thrombotic complications; the higher the level of thrombosis, the greater the risk of embolisation ^[11]. PE kills from RV failure (obstructive shock), not hypoxaemia ^[2].
Unusual-site thrombosis (CVST, mesenteric, portal, renal, hepatic veins) should trigger thrombophilia screening — ischaemic stroke can arise from hypercoagulability including protein C/S deficiency ^[20].
Obstetric complications (recurrent miscarriage, IUGR, pre-eclampsia) result from placental microvascular thrombosis.
Warfarin-induced skin necrosis is a specific complication of starting warfarin without heparin bridging in Protein C/S deficiency — affects fat-rich areas (breasts, buttocks, thighs) ^[4].
Neonatal purpura fulminans occurs in homozygous deficiency — widespread DIC and skin necrosis within hours of birth ^[6].
Post-thrombotic syndrome and CTEPH are chronic sequelae of recurrent DVT and PE respectively.
Anticoagulation-related bleeding is the main treatment complication — requires balancing thrombotic vs bleeding risk.

Active Recall - Complications of Protein S Deficiency

References

^[1] Senior notes: Block A - Leg swelling and chest pain_ deep vein thrombosis; pulmonary embolism; Thrombophilia.pdf (Protein S deficiency section, pp. 10–11) ^[2] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (DVT/PE section, p. 611) ^[4] Senior notes: Ryan Ho Haemtology.pdf (Thrombophilia screening and inherited thrombophilia management, pp. 132, 135) ^[6] Senior notes: Maksim Medicine Notes.pdf (DIC — purpura fulminans, p. 165) ^[11] Lecture slides: Respiratory Two cases of acute shortness of breath - case 1.pdf (Predisposing causes of DVT and PE, p. 5) ^[16] Senior notes: Maksim Surgery Notes.pdf (Perioperative warfarin management, p. 25) ^[19] Senior notes: MBBS Final MB (Surgery) (Felix PY Lai).pdf (Complications of DVT, p. 973) ^[20] Senior notes: Ryan Ho Neurology.pdf (Pathogenesis of ischaemic stroke — hypercoagulability, p. 74) ^[21] Senior notes: Block A - Abdominal distension_ ascites and cirrhosis.pdf (Portal vein thrombosis, p. 19) ^[22] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Nephrotic syndrome — hypercoagulability, p. 1024) ^[23] Senior notes: Introduction to Clinical pharmacology (I) (Pharmaco-Genomics, Precision Medicine).pdf (Warfarin pharmacogenomics, p. 3)

High Yield Summary

Key Points for Protein S Deficiency:

Protein S is a vitamin K-dependent natural anticoagulant synthesised in the liver, endothelial cells, megakaryocytes, and brain cells ^[1]
It acts as a cofactor for Activated Protein C (APC), which inactivates Factor Va and Factor VIIIa ^[1]
Inherited form is autosomal dominant (PROS1, 3q11.1) with three types (I, II, III) ^[1]
Prevalence ~0.9% — the most common inherited natural anticoagulant deficiency ^[1]
OR for VTE ~5.4 (less severe than AT deficiency at 16.3 and Protein C deficiency at 7.5) ^[1]
Free Protein S is the functionally active form — ~60% is bound to C4BP and inactive ^[1]
Acquired causes are far more common — pregnancy, OC pills, liver disease, acute thrombosis, DIC, nephrotic syndrome
PT and APTT are normal — need specific thrombophilia screening
Do not test during acute VTE or on anticoagulants — falsely low results ^[6]
Factor V Leiden is NOT found in Chinese — making Protein C/S and AT deficiency relatively more important in Hong Kong ^[4]
Warfarin-induced skin necrosis can occur — always bridge with heparin
Presentations: DVT, PE, unusual-site thrombosis, recurrent miscarriage, neonatal purpura fulminans (homozygous)

High Yield Summary — Differential Diagnosis

Two DDx frameworks: (a) DDx of the thrombotic tendency itself; (b) DDx of a low Protein S level on lab testing.
In Hong Kong/Chinese patients, the relevant inherited thrombophilia triad is Protein S, Protein C, and Antithrombin III deficiency. Factor V Leiden and Prothrombin G20210A are NOT found in Chinese ^[4].
Malignancy is the most important cause of unprovoked VTE ^[4] — always exclude before attributing VTE to inherited thrombophilia.
APLS is the most important acquired thrombophilia — characterised by recurrent VTE + pregnancy loss + persistent antiphospholipid antibodies ^[10].
Acquired causes of low Protein S (pregnancy, OC pills, liver disease, acute thrombosis, warfarin, inflammation) are far more common than inherited deficiency and must be excluded before making the diagnosis.
PT and APTT are normal in all three inherited natural anticoagulant deficiencies — you need specific thrombophilia screening assays.
Antithrombin deficiency is the most severe (OR 16.3, heparin resistance); Protein C deficiency has the strongest link to warfarin-induced skin necrosis; Protein S deficiency is the most prevalent (~0.9%).

High Yield Summary — Diagnosis

No formal diagnostic criteria exist — diagnosis is clinical + laboratory + exclusion of acquired causes + confirmation on repeat testing.
Free Protein S (activity and antigen) is the key measurement — not total Protein S ^[1].
Three types (I: ↓ total + ↓ free; II: normal total + normal free but ↓ activity; III: normal total + ↓ free) ^[1].
Timing is everything: do not test during acute VTE, on warfarin (withhold 2 weeks), on DOAC (withhold 2 days), during pregnancy, or during acute inflammation ^[1]^[6].
PT and APTT are normal — these test thrombin generation, not regulation.
Must exclude acquired causes (liver disease, vitamin K deficiency, pregnancy, OC pills, inflammation, nephrotic syndrome, DIC) before diagnosing inherited.
Confirm with repeat testing ≥ 6–12 weeks later and screen first-degree relatives.
Full thrombophilia panel includes: Protein C, Protein S, AT, APCR, Factor V Leiden PCR, Prothrombin G20210A, APLS panel ^[6].
In Hong Kong: skip Factor V Leiden and Prothrombin G20210A PCR in ethnic Chinese ^[4].

High Yield Summary — Management

Acute VTE: Start LMWH or UFH → transition to warfarin (with heparin bridge) or DOAC. Never start warfarin alone — risk of skin necrosis ^[4].
Duration: Protein S deficiency — individualise decision for indefinite anticoagulation ^[4]. Favour indefinite if unprovoked, recurrent, or life-threatening VTE.
Prophylaxis: Prophylactic anticoagulation in pregnancy, surgery ^[4] for all known carriers. Known hypercoagulability is an indication for perioperative LMWH bridging ^[16].
Pregnancy: LMWH throughout pregnancy + ≥ 6 weeks postpartum. Warfarin contraindicated (crosses placenta). DOACs contraindicated.
Lifestyle: Avoid OC pills (↑ oestrogen → ↓ free Protein S + ↑ procoagulant factors). Use progesterone-only or non-hormonal contraception.
Family: Screen first-degree relatives; genetic counselling for autosomal dominant inheritance.
AT deficiency is different: may need higher dose LMWH and AT concentrate because heparin requires AT-III to work ^[4].

High Yield Summary — Complications

DVT and PE are the cardinal thrombotic complications; the higher the level of thrombosis, the greater the risk of embolisation ^[11]. PE kills from RV failure (obstructive shock), not hypoxaemia ^[2].
Unusual-site thrombosis (CVST, mesenteric, portal, renal, hepatic veins) should trigger thrombophilia screening — ischaemic stroke can arise from hypercoagulability including protein C/S deficiency ^[20].
Obstetric complications (recurrent miscarriage, IUGR, pre-eclampsia) result from placental microvascular thrombosis.
Warfarin-induced skin necrosis is a specific complication of starting warfarin without heparin bridging in Protein C/S deficiency — affects fat-rich areas (breasts, buttocks, thighs) ^[4].
Neonatal purpura fulminans occurs in homozygous deficiency — widespread DIC and skin necrosis within hours of birth ^[6].
Post-thrombotic syndrome and CTEPH are chronic sequelae of recurrent DVT and PE respectively.
Anticoagulation-related bleeding is the main treatment complication — requires balancing thrombotic vs bleeding risk.

Protein S Deficiency

Epidemiology

Risk factors that "unmask" thrombosis in Protein S-deficient individuals:

Anatomy and Functional Basis

Step-by-step:

Aetiology

Classification into Three Types

Pathophysiology

Classification

Clinical Features

Symptoms

Signs

Relevant Physiological Concepts

Active Recall - Protein S Deficiency

Differential Diagnosis of Protein S Deficiency

Framework 1: DDx of a Thrombophilic State (Why Did This Patient Clot?)

Active Recall - DDx of Protein S Deficiency

References

Diagnostic Criteria for Protein S Deficiency

Step-by-Step Clinical Approach

Investigation Modalities

B. Specific Thrombophilia Screen

Active Recall - Diagnosis of Protein S Deficiency

Management of Protein S Deficiency

A. Acute VTE Treatment

C. Prophylaxis in High-Risk Situations (Asymptomatic Carriers or Post-VTE Patients)

E. Management of Special Situations

Active Recall - Management of Protein S Deficiency

References

Complications of Protein S Deficiency

Active Recall - Complications of Protein S Deficiency

References

On this page

Protein S Deficiency

Definition

Epidemiology

Prevalence

Demographics

Age of Presentation

Risk Factors for Thrombosis in Protein S Deficiency

Anatomy and Functional Basis

Normal Protein C / Protein S Anticoagulant Pathway

Where Is Protein S Synthesised?

Vitamin K Dependence

Free vs Bound Protein S

Aetiology

A. Inherited (Genetic) Protein S Deficiency

B. Acquired Protein S Deficiency

Pathophysiology

In Inherited Protein S Deficiency:

Why Predominantly Venous Thrombosis?

Thrombus Location and Special Sites

Classification

By Aetiology

By Severity

Relative Severity of Inherited Thrombophilias

Clinical Features

Symptoms

1. Symptoms of DVT

2. Symptoms of PE

3. Symptoms at Unusual Sites

4. Symptoms Specific to Protein S Deficiency Presentations

5. History Points to Elicit

Signs

1. Signs of DVT

2. Signs of PE

3. Signs of Neonatal Purpura Fulminans (Homozygous Deficiency)

4. Signs of Warfarin-Induced Skin Necrosis

5. Signs of Chronic Post-Thrombotic Syndrome (Long-term Complication)

Relevant Physiological Concepts

The Coagulation Cascade in Context

The Balance of Haemostasis

Summary Table: Inherited Natural Anticoagulant Deficiencies (Comparison)

Active Recall - Protein S Deficiency

References

Framework 1: DDx of a Thrombophilic State (Why Did This Patient Clot?)

Organising Principle: Virchow's Triad

A. Inherited Thrombophilias

B. Acquired Thrombophilias

C. Other / Mixed Causes

Framework 2: DDx of a Low Protein S Level

Distinguishing Thrombophilia from Other Patterns of "Abnormal Clotting"

Clinical Approach: Algorithm for Working Through the DDx

Summary Comparison Table: Key Differentials for Protein S Deficiency

Active Recall - DDx of Protein S Deficiency

Diagnostic Criteria for Protein S Deficiency

Why There Are No "Formal Diagnostic Criteria" Like Sapporo or ACR

Diagnostic Requirements — Practical Working Criteria

Subtype Classification on Laboratory Results

Diagnostic Algorithm

Investigation Modalities

A. First-Line Screening Investigations (Baseline Bloods)

B. Specific Thrombophilia Screen

Protein S-Specific Assays

Other Thrombophilia Assays (Ordered Simultaneously)

C. Confirmatory and Advanced Investigations

D. Investigations for VTE (The Presenting Problem)

E. Investigations to Exclude Acquired Causes of Low Protein S

Interpretation Pitfalls and Common Mistakes

Summary Table: Investigations for Protein S Deficiency

Active Recall - Diagnosis of Protein S Deficiency

References

Overarching Principles

Management Algorithm

A. Acute VTE Treatment

Phase 1: Initial Anticoagulation (Days 0–5)

Phase 2: Transition to Long-Term Anticoagulation

Special Scenario: Massive PE

B. Duration of Anticoagulation — The Key Decision

Factors Favouring Indefinite Anticoagulation

Factors Favouring Limited Duration (3–6 months)

C. Prophylaxis in High-Risk Situations (Asymptomatic Carriers or Post-VTE Patients)

1. Surgical Prophylaxis